Healthcare / Drug Manufacturers - Specialty & GenericIstanbul
$2.47
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $109.5M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
35.2x
↑EV/EBITDA
5.4x
↓ROE
3.8%
↑Gross Margin
31.2%
↓Debt/Equity
0.86
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+56.3%
FCF CAGR
—
FCF margin
-20.6%
FCF / Net income
-7.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.57B · net income $72.4M · FCF $-530.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.57B | $2.57B | $2.77B | $1.64B | $672.6M |
| Net Income | $72.4M | $72.4M | $152.6M | $-81.7M | $37.1M |
| EBITDA | $775.0M | $775.0M | $409.5M | $160.1M | $86.7M |
| EPS | 0.07 | 0.07 | 0.15 | -0.08 | 0.04 |
| Gross Margin | 31.2% | 31.2% | 22.8% | 21.6% | 17.9% |
| Operating Margin | 21.1% | 21.1% | 14.6% | 6.2% | 11.1% |
| Net Margin | 2.8% | 2.8% | 5.5% | -5.0% | 5.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.86 | 0.86 | 0.35 | 0.48 | 0.61 |
| Current Ratio | 0.99 | 0.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-530.1M | $-530.1M | $292.9M | $109.5M | $-92.3M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 8.6% | -7.6% | 11.5% |
| Valuation | |||||
| P/E | 35.18 | 35.18 | 12.14 | — | 49.39 |
| EV/EBITDA | 5.42 | 5.42 | 6.00 | 15.59 | 22.97 |
| P/B | 1.33 | 1.33 | 1.04 | 1.86 | 5.67 |
| Growth & Yield | |||||
| Revenue Growth | -7.4% | -7.4% | 69.5% | 143.4% | — |
| EPS Growth | -52.1% | -52.1% | 286.1% | -319.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.1%
EPS terminal req.
$0.22
Spread vs growth
-98.3%
5Y implied EPS CAGR
30.4%
EPS terminal req.
$0.27
Spread vs growth
-82.6%
10Y implied EPS CAGR
19.8%
EPS terminal req.
$0.43
Spread vs growth
-71.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.6%
Start / end P/E
21.6x → 34.9x
EPS bridge
0.15 → 0.07
Residual
-32.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.